The prognostic value of lymph node metastases and tumour regression grade in rectal cancer patients treated with long-course preoperative chemoradiotherapy

Colorectal Disease

Volumn 11, Issue 3, 2009, Pages 264-269

  Lindebjerg, J ^a   Spindler, Karen Lise Garm ^a   Ploen, J ^a   Jakobsen, A ^a  

^a LILLEBAELT HOSPITAL   (Denmark)

Author keywords

Locally advanced rectal cancer; N stage; Preoperative CRT; Prognosis; Survival

Indexed keywords

FLUOROURACIL; FOLINIC ACID;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER REGRESSION; CONTROLLED STUDY; FEMALE; FOLLOW UP; HUMAN; HUMAN CELL; LONGITUDINAL STUDY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; PREOPERATIVE PERIOD; PRIORITY JOURNAL; PROGNOSIS; RADIATION DOSE; RECTUM CANCER; SURVIVAL RATE; TREATMENT OUTCOME; TUMOR LOCALIZATION;

ADENOCARCINOMA; AGE FACTORS; AGED; CHEMOTHERAPY, ADJUVANT; COHORT STUDIES; COLECTOMY; FEMALE; FLUOROURACIL; HUMANS; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM STAGING; PREDICTIVE VALUE OF TESTS; PREOPERATIVE CARE; PROGNOSIS; RADIOTHERAPY DOSAGE; RADIOTHERAPY, ADJUVANT; RECTAL NEOPLASMS; RETROSPECTIVE STUDIES; RISK ASSESSMENT; SEX FACTORS; SURVIVAL ANALYSIS; TIME FACTORS; TREATMENT OUTCOME;

EID: 60549112058     PISSN: 14628910     EISSN: 14631318     Source Type: Journal    
DOI: 10.1111/j.1463-1318.2008.01599.x     Document Type: Article

References (31)

1. Hyams DM, Mamounas EP, Petrelli N et al. A clinical trial to evaluate the worth of preoperative multimodality therapy in patients with operable carcinoma of the rectum: A progress report of National Surgical Breast and Bowel Project Protocol R-03. Dis Colon Rectum 1997; 40: 131-9.
2. Sauer R, Becker H, Hohenberger W et al. Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med 2004; 351: 1731-40.
3. Gerard JP, Chapet O, Nemoz C et al. Improved sphincter preservation in low rectal cancer with high-dose preoperative radiotherapy: The lyon R96-02 randomized trial. J Clin Oncol 2004; 22: 2404-9.
4. Jakobsen A, Mortensen JP, Bisgaard C et al. Preoperative chemoradiation of locally advanced T3 rectal cancer combined with an endorectal boost. Int J Radiat Oncol Biol Phys 2005; 64: 461-5.
5. Ortholan C, Francois E, Thomas O et al. Role of radiotherapy with surgery for T3 and resectable T4 rectal cancer: Evidence from randomized trials. Dis Colon Rectum 2006; 49: 302-10.
6. Bujko K, Nowacki MP, Nasierowska-Guttmejer A et al. Sphincter preservation following preoperative radiotherapy for rectal cancer: report of a randomised trial comparing short-term radiotherapy vs. conventionally fractionated radiochemotherapy. Radiother Oncol 2004; 72: 15-24.
7. Janjan NA, Khoo VS, Abbruzzese J et al. Tumor downstaging and sphincter preservation with preoperative chemoradiation in locally advanced rectal cancer: The M. D. Anderson Cancer Center experience. Int J Radiat Oncol Biol Phys 1999; 44: 1027-38.
8. Bosset JF, Collette L, Calais G et al. Chemotherapy with preoperative radiotherapy in rectal cancer. N Engl J Med 2006; 355: 1114-23.
9. Bujko K, Nowacki MP, Nasierowska-Guttmejer A et al. Long-term results of a randomized trial comparing preoperative short-course radiotherapy with preoperative conventionally fractionated chemoradiation for rectal cancer. Br J Surg 2006; 93: 1215-23.
10. Bujko K, Michalski W, Kepka L et al. Association between pathologic response in metastatic lymph nodes after preoperative chemoradiotherapy and risk of distant metastases in rectal cancer: An analysis of outcomes in a randomized trial. Int J Radiat Oncol Biol Phys 2007; 67: 369-77.
11. Pietrzak L, Bujko K, Nowacki MP et al. Quality of life, anorectal and sexual functions after preoperative radiotherapy for rectal cancer: report of a randomised trial. Radiother Oncol 2007; 84: 217-25.
12. Den DM, Marijnen CA, Putter H et al. Risk factors for adverse outcome in patients with rectal cancer treated with an abdominoperineal resection in the total mesorectal excision trial. Ann Surg 2007; 246: 83-90.
13. Gosens MJ, van Krieken JH, Marijnen CA et al. Improvement of staging by combining tumor and treatment parameters: The value for prognostication in rectal cancer. Clin Gastroenterol Hepatol 2007; 5: 997-1003.
14. Nagtegaal ID, Marijnen CA, Kranenbarg EK, van de Velde CJ, van Krieken JH. Circumferential margin involvement is still an important predictor of local recurrence in rectal carcinoma: Not one millimeter but two millimeters is the limit. Am J Surg Pathol 2002; 26: 350-7.
15. Rodel C, Martus P, Papadoupolos T et al. Prognostic significance of tumor regression after preoperative chemoradiotherapy for rectal cancer. J Clin Oncol 2005; 23: 8688-96.
16. Benzoni E, Intersimone D, Terrosu G et al. Prognostic value of tumour regression grading and depth of neoplastic infiltration within the perirectal fat after combined neoadjuvant chemo-radiotherapy and surgery for rectal cancer. J Clin Pathol 2006; 59: 505-12.
17. Bouzourene H, Bosman FT, Seelentag W, Matter M, Coucke P. Importance of tumor regression assessment in predicting the outcome in patients with locally advanced rectal carcinoma who are treated with preoperative radiotherapy. Cancer 2002; 94: 1121-30.
18. Theodoropoulos G, Wise WE, Padmanabhan A et al. T-level downstaging and complete pathologic response after preoperative chemoradiation for advanced rectal cancer result in decreased recurrence and improved disease-free survival. Dis Colon Rectum 2002; 45: 895-903.
19. Bertolini F, Bengala C, Losi L et al. Prognostic and predictive value of baseline and posttreatment molecular marker expression in locally advanced rectal cancer treated with neoadjuvant chemoradiotherapy. Int J Radiat Oncol Biol Phys 2007; 68: 1455-61.
20. De HP, Gosens MJ, de Bruin EC et al. Cyclooxygenase 2 expression in rectal cancer is of prognostic significance in patients receiving preoperative radiotherapy. Clin Cancer Res 2007; 13: 2955-60.
21. Grossmann I, de Bock GH, Meershoek-Klein Kranenbarg WM, van d V, Wiggers T. Carcinoembryonic antigen (CEA) measurement during follow-up for rectal carcinoma is useful even if normal levels exist before surgery. A retrospective study of CEA values in the TME trial. Eur J Surg Oncol 2007; 33: 183-7.
22. Peng JJ, Cai SJ, Lu HF et al. Predicting prognosis of rectal cancer patients with total mesorectal excision using molecular markers. World J Gastroenterol 2007; 13: 3009-15.
23. Hansen JW, Jakobsen A. The importance of applicator design for intraluminal brachytherapy of rectal cancer. Med Phys 2006; 33: 3220-4.
24. Mandard AM, Dalibard F, Mandard JC et al. Pathologic assessment of tumor regression after preoperative chemoradiotherapy of esophageal carcinoma. Clinicopathologic correlations. Cancer 1994; 73: 2680-6.
25. Kapiteijn E, Marijnen CA, Nagtegaal ID et al. Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer. N Engl J Med 2001; 345: 638-46.
26. Mehta VK, Poen J, Ford J et al. Radiotherapy, concomitant protracted-venous-infusion 5-fluorouracil, and surgery for ultrasound-staged T3 or T4 rectal cancer. Dis Colon Rectum 2001; 44: 52-8.
27. Chan AK, Wong AO, Langevin JM et al. "Sandwich" preoperative and postoperative combined chemotherapy and radiation in tethered and fixed rectal cancer: Impact of treatment intensity on local control and survival. Int J Radiat Oncol Biol Phys 1997; 37: 629-37.
28. Francois Y, Nemoz CJ, Baulieux J et al. Influence of the interval between preoperative radiation therapy and surgery on downstaging and on the rate of sphincter-sparing surgery for rectal cancer: The Lyon R90-01 randomized trial. J Clin Oncol 1999; 17: 2396.
29. Onaitis MW, Noone RB, Hartwig M et al. Neoadjuvant chemoradiation for rectal cancer: Analysis of clinical outcomes from a 13-year institutional experience. Ann Surg 2001; 233: 778-85.
30. Biondo S, Navarro M, Marti-Rague J et al. Response to neoadjuvant therapy for rectal cancer: Influence on long-term results. Colorectal Dis 2005; 7: 472-9.
31. Merkel S, Mansmann U, Siassi M et al. The prognostic inhomogeneity in pT3 rectal carcinomas. Int J Colorectal Dis 2001; 16: 298-304.